Starpharma and Medicxi Partnership: Petalion Therapeutics
We didnt find Medicxi, they found us. They obviously see value in the SPL tech, as we all do. The previous CEO's game plan unfortunately did not work out as planned. The plan was to take our DEP through to demonstrate success at the the Stage 2 trial level. Surprisingly, at this point in time, it has not been picked up despite very good results. This looks like a good partnership. Medicxi have the runs on the board. Impressive leaders with the Scientific and Commercial background. You can see that these guys are not going to mess around and they will be going at this full on. I think we will see some significant outcomes over the next few years. Look forward to the webinar in May with Cheryl where hopefully we will get some updates on progress. Still think there is a lot more to play out with our DEP, Viraleze and VivaGelBV
SPL Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
